Vol 63: Unveiling the Pillars of Success: Setting Critical Quality Attributes (CQAs) during CMC Drug Development

June 22, 2023The Pathfinder 37 Min Read

In the fast-paced world of pharmaceutical development, one key factor determines the destiny of a drug—the Critical Quality Attributes (CQAs). These hidden gems can shape a drug’s safety, efficacy, and quality, ensuring its success or contributing to its downfall. From the intricate interplay of science and regulations to the patient-centric focus, setting CQAs during Chemistry, Manufacturing, and Controls (CMC) drug development is a thrilling journey fraught with challenges and triumphs. Join us as we unravel the provocative secrets behind CQA development, exposing the critical considerations and regulatory expectations that can make or break a drug’s path from the lab to the market. Brace yourself as we dive headfirst into this captivating realm where excellence and innovation collide! 


Unveiling the Pillars of Success: Setting Critical Quality Attributes (CQAs) during CMC Drug Development 


In the vast world of pharmaceutical development, ensuring a drug’s safety, efficacy, and quality is paramount. The industry follows rigorous guidelines and protocols to achieve this throughout the drug development process. One crucial aspect of this journey is the establishment of CQAs during CMC drug development. These attributes serve as the pillars that support the overall success of a drug, dictating its performance, safety, and efficacy. In this article, we will delve into the exciting realm of CQAs, exploring their significance, considerations, and impact on the journey from lab to market. 

Defining CQAs: A Stepping Stone to Excellence 

Critical Quality Attributes are the measurable characteristics that determine the identity, potency, safety, purity, and quality of a drug substance or drug product. They are the quantifiable parameters crucial for ensuring the consistency and reproducibility of the drug throughout its lifecycle. These attributes can encompass various parameters, including physical, chemical, biological, or microbiological properties. 


Consideration #1: Safety and Efficacy 


When setting CQAs, the primary consideration is ensuring the safety and efficacy of the drug. Extensive research and analysis are conducted to identify the attributes directly impacting the drug’s therapeutic effect. This involves understanding the drug’s mechanism of action, target interactions, and the specific qualities that contribute to its desired effect. By defining CQAs based on safety and efficacy, manufacturers can mitigate potential risks and enhance patient outcomes. 

When setting CQAs, safety, and efficacy are of utmost importance. Here are some key points to consider: 

  • Identification of target attributes: The first step is identifying the characteristics that directly influence the drug’s safety and efficacy. For example, attributes such as potency, selectivity, and duration of action may be critical in the case of cardiovascular medication. 
  • Impurity profiling: Determining acceptable levels of impurities is crucial for ensuring patient safety. CQAs related to impurities might include limits on residual solvents, genotoxic impurities, or process-related impurities. 
  • Biological activity and stability: CQAs may include parameters such as assay potency, biological activity, or stability under various storage conditions. For instance, a biological drug’s CQAs may consist of measures of protein conformation, glycosylation patterns, or potency assays. 


Consideration #2: Process Understanding and Control 


An in-depth understanding of the manufacturing process is essential for establishing CQAs. This involves identifying critical process parameters (CPPs) and critical material attributes (CMAs) that significantly impact the drug’s quality. By conducting risk assessments and employing quality by design (QbD) principles, manufacturers can gain valuable insights into the cause-and-effect relationships between process parameters and CQAs. This knowledge empowers them to control and optimize the manufacturing process, producing consistent quality and robust products. 

A thorough understanding of the manufacturing process is essential for establishing CQAs. Consider the following points: 

  • Critical process parameters (CPPs): Identify the process parameters that significantly impact the CQAs. These parameters should be closely monitored and controlled. For example, parameters such as granulation time, compression force, and drying temperature may be critical for tablet hardness, disintegration time, and content uniformity in tablet manufacturing. 
  • Critical material attributes (CMAs): Raw materials used in the manufacturing process can significantly influence CQAs. Parameters like particle size, polymorphic form, or moisture content may be critical for drug substance attributes. Similarly, factors like excipient properties, impurity profiles of raw materials, or particle size distribution can be crucial for drug product attributes. 
  • Process validation: CQAs should be defined based on process validation studies. Manufacturers can establish robust control strategies by studying the impact of process changes or variations on CQAs. For example, mixing time, pH, or temperature variations during fermentation might impact protein structure and purity. 


Consideration #3: Regulatory Compliance 


Pharmaceutical development is a highly regulated field, and adherence to regulatory guidelines is crucial. Regulatory authorities require manufacturers to demonstrate a thorough understanding of their drug’s CQAs and the associated control strategies. By documenting and justifying the selection of CQAs, manufacturers can ensure compliance and expedite the regulatory review process. Additionally, full CQA considerations pave the way for successful technology transfer, scale-up, and post-approval changes. 

Adhering to regulatory guidelines is essential for successful drug development and approval. Consider the following: 

  • Documentation and justification: Regulatory authorities require manufacturers to document and justify the selection of CQAs. This includes providing scientific rationale, experimental data, and risk assessments. Manufacturers must demonstrate how CQAs were established, controlled, and monitored throughout the product’s lifecycle. 
  • Post-approval changes: CQAs play a significant role in post-approval changes, such as process scale-up, site transfer, or formulation modifications. Any changes impacting CQAs must be thoroughly evaluated and justified to ensure product consistency and patient safety. 
  • Stability testing: Stability studies are essential for establishing CQAs related to shelf life and storage conditions. Manufacturers must demonstrate that the drug remains within acceptable quality limits throughout its intended shelf life. 


Consideration #4: Patient-Centric Approach 


Pharmaceutical development is ultimately centered around patients’ well-being. It is vital to consider the needs and preferences of patients when establishing CQAs. Factors such as dosage form, route of administration, ease of use, and patient tolerance play a significant role in determining the success of a drug. Manufacturers can enhance patient compliance, satisfaction, and overall treatment outcomes by incorporating patient-centric attributes into the CQA framework. 

Considering patients’ needs and preferences helps ensure successful treatment outcomes. Consider the following: 

  • Dosage form attributes: CQAs related to dosage forms may include characteristics like tablet hardness, disintegration time, or taste masking for solid oral dosage forms. For parenteral formulations, attributes like particle size, viscosity, or injection site reaction may be critical. 
  • Patient compliance and ease of use: CQAs can address patient compliance by focusing on tablet size, frequency of dosing, or ease of administration. For instance, designing a once-daily extended-release formulation can improve patient adherence. 


  • Allergenicity and tolerability: Some patients may have specific allergies or sensitivities to certain excipients or ingredients. CQAs can be established to ensure the absence of allergens or to set limits on potential irritants. 


Consideration #5: Analytical Techniques and Methodologies 


Accurate and reliable analytical techniques are instrumental in assessing CQAs. Manufacturers must select appropriate methodologies capable of detecting and quantifying the critical attributes at different stages of the drug’s development and production. Advanced analytical technologies, such as chromatography, spectroscopy, and mass spectrometry, enable comprehensive characterization and evaluation of CQAs, ensuring the drug consistently meets the desired standards. 

Accurate and reliable analytical techniques are instrumental in assessing Critical Quality Attributes (CQAs) throughout the drug development process. Here are some key points to consider: 

  • Method Development and Validation: Rigorous method development and validation are essential for establishing robust analytical techniques. This involves selecting appropriate analytical methods, ensuring their accuracy, precision, specificity, and sensitivity, and validating them according to regulatory guidelines. Examples of CQAs in this context may include method accuracy, precision, linearity, the limit of detection (LOD), the limit of quantitation (LOQ), and robustness. 
  • Impurity Analysis: Determining the levels of impurities and degradants is critical for assessing drug safety and purity. CQAs related to impurity analysis may include identifying and quantifying known and unknown impurities, related substances, residual solvents, or process-related impurities. 
  • Stability-Indicating Methods: CQAs may focus on developing stability-indicating methods that can accurately assess the stability and degradation of the drug product over time. These methods should be able to differentiate between the active pharmaceutical ingredient (API) and its degradation products, ensuring that the drug remains within acceptable quality limits during storage and throughout its shelf life. 
  • Physicochemical Characterization: CQAs may involve the comprehensive physicochemical characterization of the drug substance or product. This can include parameters such as particle size and distribution, polymorphic forms, solubility, dissolution rate, pH, viscosity, or refractive index. 
  • Bioavailability and Bioequivalence: CQAs can be established to assess the bioavailability and bioequivalence of a drug product. This may involve developing methods such as in vitro dissolution testing or pharmacokinetic studies to ensure that the drug product delivers the intended amount of the API to the systemic circulation, thus providing a consistent therapeutic effect. 
  • Process Analytical Technology (PAT): Implementing PAT principles can lead to real-time monitoring and control of critical quality parameters during manufacturing. CQAs related to PAT can include parameters such as blend uniformity, content uniformity, moisture content, or particle size distribution. These can be monitored using near-infrared spectroscopy (NIRS), Raman spectroscopy, or in-line process analyzers. 

By employing advanced analytical techniques and methodologies, manufacturers can effectively assess CQAs and ensure their drug products’ consistent quality, efficacy, and safety throughout the development and manufacturing processes. 


More information on how and when to develop CQAs and what are the Regulatory Expectations 


To get more detailed information on how and when to develop Critical Quality Attributes (CQAs) and understand regulatory expectations, you can refer to the following sources: 

  1. Regulatory Guidelines: Consult regulatory guidelines provided by authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). These guidelines provide detailed information on CQA development, regulatory expectations, and considerations for drug development. 
  1. ICH Q8 (R2) Pharmaceutical Development: This guideline focuses on the principles of pharmaceutical development, including establishing CQAs. It provides a systematic approach to designing, developing, and optimizing the pharmaceutical dosage form while emphasizing the importance of understanding and controlling the critical aspects of the product and manufacturing process. 
  1. ICH Q9 Quality Risk Management: This guideline provides a framework for implementing quality risk management in the pharmaceutical industry. It offers insights into identifying and assessing risks related to CQAs and provides risk mitigation and control strategies. 
  1. ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities): This guideline focuses on developing and manufacturing drug substances. It provides recommendations on developing and characterizing CQAs for drug substances, including considerations for starting materials, impurities, and control strategies. 
  1. Regulatory Authority Websites: Visit the official websites of regulatory authorities such as the FDA, EMA, or other national regulatory bodies. These websites provide regulatory guidance, industry-specific guidelines, and updates on regulatory expectations related to CQAs. 
  1. Scientific Journals and Publications: Keep track of scientific journals and publications on pharmaceutical development, quality control, and regulatory affairs. These sources often feature articles, case studies, and research papers that provide insights into CQA development and regulatory considerations. 
  1. Industry Conferences and Events: Attend industry conferences, seminars, and workshops on pharmaceutical development, quality assurance, and regulatory compliance. These events provide opportunities to learn from experts, participate in discussions, and gain practical knowledge regarding CQA development and regulatory expectations. 

Remember, CQA development and regulatory expectations may vary based on the specific region and type of drug product. It is crucial to stay current with the latest guidelines and regulations applicable to your target market. Consulting with regulatory experts and professionals in the field can also provide valuable insights and guidance. 




Setting Critical Quality Attributes (CQAs) during CMC drug development is not just a mere formality but the cornerstone of success for pharmaceutical products. By carefully considering factors such as safety, efficacy, process understanding, regulatory compliance, and a patient-centric approach, manufacturers can establish a robust framework for achieving consistent quality and reliable performance. 

The journey of CQA development requires a deep understanding of the drug’s mechanism of action, critical process parameters, and the impact of raw materials. It demands adherence to stringent regulatory guidelines and the ability to adapt to evolving industry standards. Additionally, a patient-centric approach ensures that drugs meet the needs and preferences of those who rely on them, enhancing treatment outcomes and patient satisfaction. 

By establishing clear and measurable CQAs, manufacturers can mitigate risks, optimize manufacturing processes, and navigate regulatory challenges more effectively. Thorough documentation, justification, and post-approval change management contribute to the overall success of a drug’s development. At the same time, analytical techniques provide the necessary tools to evaluate and monitor CQAs throughout the product’s lifecycle. 

In this captivating realm where science and regulations intersect, CQAs serve as beacons of excellence, guiding pharmaceutical development toward its ultimate goal: delivering safe, effective, and high-quality medications to patients worldwide. Embracing the challenges and complexities of CQA development paves the way for groundbreaking innovations, shaping the pharmaceutical industry’s future. 

So, let us celebrate the unsung heroes of drug development—the Critical Quality Attributes—and recognize their vital role in transforming scientific discoveries into life-changing treatments. With each meticulously defined CQA, we advance closer to a world where every patient can access the safe and effective medications they deserve. 

Upcoming Event

Oct 22


October 22-25, 2023 

Orlando, FL, USA

Orange County Convention Center

The Pathfinder

The latest in biotech for your ears

The VirtualPharm Podcast is an audio series that covers topics related to compliance and regulatory affairs in the Lifesciences industry. Each episode, hosted by an expert in the topic with decades of experience, offers listeners detailed insight into the changing regulatory environment.

Subscribe to the Pathfinder

    Lets discuss your product